Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > The overall pipeline

<< Previous

Bullboard Posts

Next >>

Comment by DeathXray33on Nov 10, 2024 2:24pm

136 Views

Post# 36305769

RE:RE:The overall pipeline

CancerSlayer wrote:
DJDawg wrote: Thinking on the competition for BCG therapy I remain convinced that the key to longterm success is as follows.

- get BTD to show wider pool of investors that serious drug with good outcomes and FDA respect despite being a tiny tiny company on the tsx venture
- get a financial bump of some kind with the BTD
- use the money to widen the pipeline to show IV rutherrin could do amazing things for typically fatal GBM and advanced NSCLC
- get some kind of thing going with very interesting HSV data to further show the different pipelines

If they can show the world that not a one trick NMIBC pony then they will shoot up as the more viable avenues of sucess = more derisking compared to one drug and one narrow disease type of biotech company.

Agree....would also really like to see the preclinical versatility of this drug begin to clinically shine. If TLT can demonstrate that our versatile base compound can not only be applied to other indications systemically/intravenously, but also respond to a more simplified/external activation source (i.e. X-ray, other FDA approved compound, nano scintillation, etc.) in a highly unmet condition, both the degree & trajectory of our long term success would rise exponentially imo.

We are nearing the opportunity to rapidly ascend from being a one-hit wonder to possibly being the new evergreen in the treatment of cancer/chronic disease. JMO.